Gene Editing

20 08, 2024

World’s first gene editing therapy for blood disorder to be available to hundreds of patients in England

2024-08-20T13:52:29+00:00

Patients in England with severe beta-thalassaemia will be amongst the first in Europe to benefit from one-time gene therapy exagamglogene autotemcel. Exa-cel is the world’s first CRISPR-based gene therapy and the first gene therapy available in Europe for treating severe beta-thalassaemia...

World’s first gene editing therapy for blood disorder to be available to hundreds of patients in England2024-08-20T13:52:29+00:00
6 08, 2024

FDA Approves First T Cell Receptor (TCR) Gene Therapy

2024-08-06T19:21:42+00:00

Tecelra is the first FDA-approved T cell receptor (TCR) gene therapy. The product is an autologous T cell immunotherapy composed of a patient’s own T cells. T cells in Tecelra are modified to express a TCR that targets MAGE-A4, an antigen expressed by cancer cells in synovial sarcoma...

FDA Approves First T Cell Receptor (TCR) Gene Therapy2024-08-06T19:21:42+00:00
2 03, 2023

Avance Biosciences™ licenses SeQure Dx’s GUIDE-seq off-target NGS analysis technology

2024-08-09T18:08:43+00:00

Avance Biosciences™ (Avance), a leading CRO that provides GLP/CGMP-compliant biological testing services that aid drug development and manufacturing, announced today that it has signed a licensing agreement with SeQure Dx, a cutting-edge gene-editing diagnostics company...

Avance Biosciences™ licenses SeQure Dx’s GUIDE-seq off-target NGS analysis technology2024-08-09T18:08:43+00:00
Go to Top